TY - JOUR
T1 - Facilitating return of actionable genetic research results from a biobank repository
T2 - participant uptake and utilization of digital interventions
AU - Phung, Lillian
AU - Wood, Elisabeth
AU - Egleston, Brian
AU - Hoffman-Andrews, Lily
AU - Ofidis, Demetrios
AU - Howe, Sarah
AU - Mim, Rajia
AU - Griffin, Hannah
AU - Fetzer, Dominique
AU - Owens, Anjali
AU - Domchek, Susan
AU - Pyeritz, Reed
AU - Katona, Bryson
AU - Kallish, Staci
AU - Sirugo, Giorgio
AU - Weaver, JoEllen
AU - Nathanson, Katherine L
AU - Rader, Daniel J
AU - Bradbury, Angela R
N1 - Copyright © 2024. Published by Elsevier Inc.
PY - 2024/8/24
Y1 - 2024/8/24
N2 - Research participants report interest in receiving genetic research results. How best to return results remains unclear. In this randomized pilot study, we sought to assess the feasibility of returning actionable research results through a two-step process including a patient-centered digital intervention as compared with a genetic counselor (GC) in the Penn Medicine biobank. In Step 1, participants with an actionable result and procedural controls (no actionable result) were invited to digital pre-disclosure education and provided options for opting out of results. In Step 2, those with actionable results who had not opted out were randomized to receive results via a digital disclosure intervention or with a GC. Five participants (2%) opted out of results after Step 1. After both steps, 52 of 113 (46.0%) eligible cases received results, 5 (4.4%) actively declined results, 34 (30.1%) passively declined, and 22 (19.5%) could not be reached. Receiving results was associated with younger age (p < 0.001), completing pre-disclosure education (p < 0.001), and being in the GC arm (p = 0.06). Being older, female, and of Black race were associated with being unable to reach. Older age and Black race were associated with passively declining. Forty-seven percent of those who received results did not have personal or family history to suggest the mutation, and 55.1% completed clinical confirmation testing. The use of digital tools may be acceptable to participants and could reduce costs of returning results. Low uptake, disparities in uptake, and barriers to confirmation testing will be important to address to realize the benefit of returning actionable research results.
AB - Research participants report interest in receiving genetic research results. How best to return results remains unclear. In this randomized pilot study, we sought to assess the feasibility of returning actionable research results through a two-step process including a patient-centered digital intervention as compared with a genetic counselor (GC) in the Penn Medicine biobank. In Step 1, participants with an actionable result and procedural controls (no actionable result) were invited to digital pre-disclosure education and provided options for opting out of results. In Step 2, those with actionable results who had not opted out were randomized to receive results via a digital disclosure intervention or with a GC. Five participants (2%) opted out of results after Step 1. After both steps, 52 of 113 (46.0%) eligible cases received results, 5 (4.4%) actively declined results, 34 (30.1%) passively declined, and 22 (19.5%) could not be reached. Receiving results was associated with younger age (p < 0.001), completing pre-disclosure education (p < 0.001), and being in the GC arm (p = 0.06). Being older, female, and of Black race were associated with being unable to reach. Older age and Black race were associated with passively declining. Forty-seven percent of those who received results did not have personal or family history to suggest the mutation, and 55.1% completed clinical confirmation testing. The use of digital tools may be acceptable to participants and could reduce costs of returning results. Low uptake, disparities in uptake, and barriers to confirmation testing will be important to address to realize the benefit of returning actionable research results.
U2 - 10.1016/j.xhgg.2024.100346
DO - 10.1016/j.xhgg.2024.100346
M3 - Article
C2 - 39183478
SN - 2666-2477
VL - 5
SP - 100346
JO - Human Genetics and Genomics Advances
JF - Human Genetics and Genomics Advances
IS - 4
ER -